10-Q: Avai Bio Reports Q2 2026 Results: Persistent Losses, Cash Concerns

Avai Bio, Inc. (AVAI) filed its Q2 2026 10-Q, revealing no revenue, increased net losses, and significant concerns regarding its ability to continue as a going concern.

Summary

• Avai Bio, Inc. reported its financial results for the quarter ended June 30, 2026.
• The company generated no revenue during the quarter, similar to the prior year's period.
• Total operating expenses decreased by 14% to $419,783 from $487,589 in the same period last year, primarily due to reductions in marketing and professional fees.
• Other expenses significantly increased to $132,258 from $0 in the prior year, including interest and discount on convertible notes, interest on loan payable, and a loss on disposal of a subsidiary.
• The net loss for the quarter was $552,041, an increase of 13% from $487,589 in the prior year's quarter.
• The company's cash balance increased to $83,586 from $23,145.
• However, the company has a substantial working capital deficit and faces substantial doubt about its ability to continue as a going concern, relying on future investment capital.
• Intangible assets increased to $158,898 from $105,542, largely due to the acquisition of Wellness Assessment API costs.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the company's continued lack of revenue, significant net losses, and substantial doubt about its ability to continue as a going concern, despite ongoing efforts to secure capital.

Positives

• Cash balance increased to $83,586 from $23,145.
• Total operating expenses decreased by 14% to $419,783 from $487,589, driven by reductions in marketing and professional fees.
• The company is actively pursuing capital through various financing activities, including convertible notes and loans from related parties and third parties.

Negatives

• No revenue was generated in the quarter, mirroring the previous year's performance.
• Net loss increased by 13% to $552,041 from $487,589 in the prior year's quarter.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a significant working capital deficit of $3,860,035 as of June 30, 2026.
• Stockholders' deficit increased to $3,222,566 from $2,815,155.
• Other expenses increased significantly to $132,258 due to interest, discounts on convertible notes, and loss on disposal of a subsidiary.

Risks

• Limited operating history in an evolving industry makes future prospects difficult to evaluate and increases the risk of failure.
• The company may not be able to achieve profitability or generate positive cash flow from operations.
• Substantial additional capital is required to support business growth and operations, and this capital may not be available on acceptable terms.
• The company depends on key personnel and the ability to attract and retain qualified individuals.
• There is a limited public market for the company's common stock, leading to potential volatility and difficulty in selling shares.
• The company's disclosure controls and procedures were found to be not effective.
• Inability to commercialize acquired technologies, such as Avant! AI and InstantFAME platforms, despite significant investment.
• Cybersecurity oversight gaps exist due to the lack of a formal enterprise risk management program and a cybersecurity subcommittee.

Future Outlook

The company anticipates continued dependence on additional investment capital to fund operating expenses and intends to raise additional funds through the capital markets. There is no assurance of success in these endeavors or in becoming financially viable.

Management Comments

• Management believes its technology can provide a self-sustained system that prepares data from unlabeled information and analyzes it using proprietary supervised learning techniques, improving data efficiency.
• Management is developing plans to alleviate negative trends and conditions, but the business plan is speculative and unproven.
• Management expects that net losses will continue and the working capital deficiency will increase.
• Management concluded that disclosure controls and procedures were not effective as of June 30, 2026.

Industry Context

StockSavvy.ai notes that Avai Bio operates in the rapidly evolving AI and IT consulting sector. While the company focuses on AI-driven solutions, its lack of revenue and ongoing losses are significant concerns, especially given the competitive landscape and the capital-intensive nature of AI development.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceedings and is not aware of any pending or potential legal actions.

Related Party Transactions

• Loans from related parties (secretary, director, shareholder) totaling $114,328 (secretary), $128,645 (director), $30,000 (shareholder), and $530,000 (shareholder IGOR 1 CORP) are outstanding, generally unsecured and non-interest bearing.
• A loan from shareholder Marieta Seiranova of $7,000 was advanced and repaid during the year ended March 31, 2026.
• A subsidiary received advances totaling $124,590, which were settled by issuing common stock in March 2026.

Stakeholder Impact

• Shareholders face significant dilution risk from future equity offerings and potential volatility in stock price due to limited market liquidity.
• Creditors and lenders face uncertainty regarding the company's ability to meet its financial obligations due to its going concern issues.
• Employees may face job insecurity given the company's financial precariousness and reliance on future funding.

Next Steps

• Continue to develop and market products.
• Seek additional capital through equity or debt financings.
• Improve internal controls over financial reporting.
• Position the company to raise additional funds through capital markets.

Key Dates

Recommendation

The company exhibits severe financial distress with no revenue, increasing losses, a persistent going concern issue, and a substantial need for capital. The lack of progress in commercializing its technology and the ineffectiveness of its internal controls further exacerbate these risks, making it a highly speculative investment with a significant probability of failure.

Keywords

AI, Artificial Intelligence, Technology, Information Technology, Software Development, Startup, Venture Capital, Financing